7th Glioblastoma Drug Development Summit

The 7th Glioblastoma Drug Development Summit is a three-day, industry-focused event dedicated to accelerating progress in therapies for glioblastoma and glioma, two of the most aggressive and underfunded brain cancers. The summit will take place from February 17–19, 2026 at The Royal Sonesta Boston in Cambridge, MA, USA. This forum brings together biotech, pharmaceutical, clinical, investment, and academic experts to tackle scientific challenges and clinical limitations hampering effective treatment. Attendees explore strategies to shorten the path from discovery to bedside, including combination therapies, robust preclinical and clinical frameworks, and leveraging AI and multi-omics approaches for improved patient outcomes.

Over three transformative days, participants will engage in six deep-dive workshops, interactive roundtables, poster sessions, and networking opportunities with more than 90 industry leaders. The summit’s agenda includes sessions on next-generation therapeutic strategies, investment and partnership landscapes, regulatory insights, and the latest data on CAR-T, biomarkers, clinical trial design, and translational science. With industry representation from companies such as Merck, AstraZeneca, Laminar Pharma, CNS Pharmaceuticals, and Imvax, the summit aims to transform scientific ambition into patient impact and speed the delivery of meaningful glioblastoma treatments.